Seaport Jumps 17% After Upsized $255 Million US IPO

Seaport Therapeutics stormed onto the public market Thursday, with shares leaping 17% after the drugmaker raised nearly $255 million in an upsized US initial public offering.

The sharp first-day gain points to strong investor appetite for new biotech listings at a moment when public markets have often treated the sector cautiously. Seaport did more than complete an offering; it priced a larger deal and still drew enough demand to send the stock higher in its trading debut. That combination suggests investors saw more than a routine listing.

For Seaport, the move delivers fresh capital and a public-market vote of confidence. For the broader market, it offers another test of whether investors will back growth-focused drug developers despite persistent pressure on financing conditions. Reports indicate buyers responded positively to both the company’s fundraising scale and its entry into the market.

A 17% debut after an upsized IPO sends a simple message: investors were willing to pay up for Seaport’s market entry.

That does not erase the hard part ahead. Public investors can reward a biotech story on day one, then demand proof on every milestone after that. Seaport now faces a new level of scrutiny as traders and long-term holders watch how it uses the proceeds, how the stock settles after the opening surge, and whether market enthusiasm can hold.

What happens next matters beyond one company. If Seaport’s strong debut holds, it could encourage other drugmakers to test the US IPO market and give bankers a fresh data point on biotech risk appetite. If the gains fade, the listing may still count as a fundraising win, but the real verdict will come from how the market values Seaport once the opening excitement gives way to execution.